See more : PT Triniti Dinamik (TRUE.JK) Income Statement Analysis – Financial Results
Complete financial analysis of Valneva SE (VLAP.PA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Valneva SE, a leading company in the Biotechnology industry within the Healthcare sector.
- Allego N.V. (ALLGF) Income Statement Analysis – Financial Results
- UPM-Kymmene Oyj (RPL.DE) Income Statement Analysis – Financial Results
- Lions Bay Capital Inc. (LBI.V) Income Statement Analysis – Financial Results
- Andhra Paper Limited (ANDHRAPAP.NS) Income Statement Analysis – Financial Results
- Wool Industry Tria Alfa S.A. (AAAK.AT) Income Statement Analysis – Financial Results
Valneva SE (VLAP.PA)
About Valneva SE
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 153.71M | 361.30M | 348.09M | 110.32M | 126.20M | 113.04M | 105.29M | 94.06M | 78.36M | 36.92M | 30.45M | 3.43M | 10.26M | 8.40M | 3.10M | 3.42M | 866.00K | 2.33M | 3.01M |
| Cost of Revenue | 100.88M | 324.44M | 187.92M | 54.30M | 49.97M | 43.43M | 45.98M | 43.08M | 46.96M | 17.14M | 16.51M | 11.10M | 6.72M | 6.54M | 5.26M | 2.75M | 1.68M | 726.00K | 475.00K |
| Gross Profit | 52.84M | 36.86M | 160.17M | 56.02M | 76.23M | 69.60M | 59.31M | 50.99M | 31.40M | 19.78M | 13.94M | -7.66M | 3.54M | 1.86M | -2.16M | 673.00K | -817.00K | 1.60M | 2.54M |
| Gross Profit Ratio | 34.37% | 10.20% | 46.01% | 50.78% | 60.40% | 61.58% | 56.33% | 54.20% | 40.07% | 53.57% | 45.78% | -223.38% | 34.50% | 22.11% | -69.80% | 19.69% | -94.34% | 68.83% | 84.22% |
| Research & Development | 59.89M | 104.92M | 173.28M | 84.45M | 37.88M | 12.19M | 23.36M | 24.59M | 25.37M | 22.24M | 21.42M | 12.89M | 12.17M | 13.13M | 9.87M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 47.80M | 34.07M | 47.61M | 38.01M | 27.51M | 36.30M | 15.55M | 14.41M | 14.39M | 14.14M | 14.72M | 4.18M | 262.00K | 3.69M | 3.06M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 48.75M | 23.51M | 23.64M | 7.52M | 14.62M | 11.74M | 17.88M | 16.64M | 9.12M | 2.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 96.55M | 57.58M | 71.25M | 45.52M | 42.13M | 48.04M | 33.42M | 31.05M | 23.52M | 14.14M | 14.72M | 4.18M | 262.00K | 3.69M | 3.06M | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | -21.52M | -12.20M | -22.98M | -18.85M | -3.07M | 19.83M | 6.49M | 37.79M | 2.48M | 7.15M | -91.00K | -798.00K | 8.39M | -636.00K | 3.38M | 3.83M | 3.97M | 1.82M | 3.97M |
| Operating Expenses | 134.92M | 150.31M | 221.56M | 111.13M | 76.95M | 63.34M | 63.27M | 93.43M | 51.36M | 43.53M | 36.05M | 16.26M | 8.65M | 16.81M | 3.38M | 3.83M | 3.97M | 1.82M | 3.97M |
| Cost & Expenses | 235.80M | 474.75M | 409.48M | 165.43M | 126.92M | 106.77M | 109.25M | 136.51M | 98.32M | 60.68M | 52.56M | 16.26M | 15.37M | 16.81M | 8.64M | 6.57M | 5.65M | 2.55M | 4.44M |
| Interest Income | 1.21M | 260.00K | 249.00K | 119.00K | 199.00K | 178.00K | 72.00K | 290.00K | 3.10M | 225.00K | 191.00K | 435.00K | 757.00K | 389.00K | 312.00K | 972.00K | 550.00K | 91.00K | 34.00K |
| Interest Expense | 23.33M | 19.05M | 16.96M | 10.74M | 2.63M | 3.79M | 5.06M | 6.09M | 9.72M | 4.39M | 1.21M | 533.00K | 699.00K | 786.00K | 161.00K | 207.00K | 154.00K | 25.00K | 81.00K |
| Depreciation & Amortization | 17.58M | 21.04M | 14.28M | 9.80M | 8.53M | 6.83M | 11.14M | 11.27M | 11.44M | 12.36M | 9.06M | 4.78M | 3.32M | 2.62M | 1.59M | 1.31M | 1.22M | 328.00K | 1.52M |
| EBITDA | -57.72M | -99.39M | -46.87M | -46.11M | 9.71M | 12.85M | 3.64M | -31.47M | 9.76M | -9.19M | -13.36M | -7.69M | 795.00K | -6.08M | -4.70M | -1.82M | -3.02M | 605.00K | 998.00K |
| EBITDA Ratio | -37.55% | -31.32% | -13.46% | -41.08% | 8.01% | 12.74% | 6.98% | -0.97% | -1.58% | -30.38% | -42.13% | -220.69% | -10.04% | -69.04% | -127.58% | -53.31% | -348.50% | 23.06% | 30.89% |
| Operating Income | -82.09M | -113.44M | -61.39M | -55.11M | 1.50M | 6.26M | -3.95M | -42.57M | -19.93M | -23.82M | -20.86M | -12.83M | -4.45M | -8.42M | -6.30M | -3.15M | -4.79M | -221.00K | -1.43M |
| Operating Income Ratio | -53.40% | -31.40% | -17.64% | -49.95% | 1.19% | 5.54% | -3.76% | -45.26% | -25.44% | -64.50% | -68.50% | -374.03% | -43.37% | -100.26% | -203.33% | -92.28% | -552.54% | -9.49% | -47.49% |
| Total Other Income/Expenses | -16.54M | -31.37M | -8.59M | -10.18M | -59.00K | -2.91M | -8.61M | -6.26M | -13.64M | -2.12M | -2.77M | -56.00K | 1.43M | -397.00K | 3.58M | 765.00K | 396.00K | -25.00K | 34.00K |
| Income Before Tax | -98.63M | -144.82M | -69.98M | -65.30M | -870.00K | 3.35M | -12.56M | -48.83M | -20.39M | -25.94M | -23.63M | -12.89M | -4.39M | -9.45M | -6.14M | -2.39M | -4.39M | -246.00K | -1.40M |
| Income Before Tax Ratio | -64.16% | -40.08% | -20.10% | -59.19% | -0.69% | 2.96% | -11.93% | -51.91% | -26.03% | -70.25% | -77.60% | -375.66% | -42.80% | -112.57% | -198.45% | -69.89% | -506.81% | -10.56% | -46.36% |
| Income Tax Expense | 2.80M | -1.54M | 3.45M | -909.00K | 874.00K | 88.00K | -1.08M | 356.00K | 224.00K | 334.00K | 348.00K | 96.00K | 26.00K | -1.49M | 0.00 | 24.00K | -1.03M | -3.00K | -176.00K |
| Net Income | -101.43M | -143.28M | -73.43M | -64.39M | -1.74M | 3.26M | -11.48M | -49.18M | -20.62M | -26.27M | -24.11M | -14.84M | -4.42M | -7.96M | -6.14M | -2.39M | -3.36M | -243.00K | -1.22M |
| Net Income Ratio | -65.99% | -39.66% | -21.09% | -58.37% | -1.38% | 2.89% | -10.91% | -52.29% | -26.31% | -71.15% | -79.19% | -432.56% | -43.06% | -94.84% | -198.45% | -69.89% | -388.22% | -10.43% | -40.52% |
| EPS | -0.73 | -1.24 | -0.75 | -0.71 | -0.02 | 0.04 | -0.15 | -0.66 | -0.28 | -0.47 | -0.61 | -0.70 | -0.21 | -0.46 | -0.42 | -0.14 | -0.26 | -0.02 | -0.12 |
| EPS Diluted | -0.73 | -1.24 | -0.75 | -0.71 | -0.02 | 0.04 | -0.15 | -0.66 | -0.28 | -0.47 | -0.61 | -0.70 | -0.21 | -0.46 | -0.42 | -0.14 | -0.26 | -0.02 | -0.12 |
| Weighted Avg Shares Out | 138.94M | 115.47M | 97.62M | 90.76M | 91.74M | 80.53M | 76.55M | 74.66M | 72.74M | 55.49M | 39.34M | 21.27M | 20.99M | 17.49M | 14.63M | 16.84M | 13.06M | 10.20M | 10.20M |
| Weighted Avg Shares Out (Dil) | 138.62M | 115.47M | 97.62M | 90.76M | 91.74M | 81.60M | 77.45M | 74.66M | 72.74M | 55.49M | 39.34M | 21.27M | 21.09M | 17.49M | 14.63M | 16.84M | 13.06M | 10.20M | 10.20M |
Source: https://incomestatements.info
Category: Stock Reports